On June 1, Tempus AI rose 5.32% in regular trading, trading at $53.165/share, with trading volume of $211 million. The rally was driven by the continued market reaction to the FDA approval of the company's tumor-only xT CDx next-generation sequencing platform for comprehensive genomic profiling of solid tumors.
The approval, announced in late May, makes Tempus the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company stated that it can now migrate its entire DNA-based solid tumor product portfolio to the newly approved platform. Tempus expects the approval to deliver an estimated $200 increase in average selling price beginning in 2027.
Multiple catalysts have supported the stock in recent sessions. The company also upgraded its Tempus Hub platform with an Agentic AI architecture, integrating large language models and generative AI capabilities with real-time genomic patient data. Additionally, Q1 revenue reached $348.1 million, up 36.1% year-over-year, exceeding market expectations, with core diagnostics revenue growing 34.7%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments